Sign in
Taking people in South KoreaPhase 3

Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease

Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Deagu, Incheon, and Seoul, South KoreaSee the 10 sitesAlso in 25 other countries, 231 sites
Trial code
Registry title
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Status
Recruiting
Phase
Phase 3
People taking part
650 people, planned
Started
2 Dec 2025
Expected to end
20 Jul 2029
Type of study
Interventional
Treatments tested
  • KarXT
  • KarX-EC
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 55 to 90 with agitation linked to Alzheimer's disease who finished study CN012-0023 or CN012-0024 and have a caregiver.

Age
55 to 90 years
Sex
All sexes
Disease stage
Agitation associated with Alzheimer's disease.
Earlier treatment
Must have completed study CN012-0023 or CN012-0024 as the protocol requires.

Main reasons for not taking part

  • Clinically significant heart, lung, kidney, blood, gut, hormone, immune, skin, nerve or cancer disease
  • Any other condition the investigator thinks could harm the person's safety or the study results
  • Other exclusion rules set by the protocol

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants must have completed study CN012-0023 or CN012-0024 per protocol
  • Participants must have an identified caregiver who has sufficient contact (approximately 8 hours over a week)

Who cannot take part

  • Participants must not have clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results
  • Other protocol-defined Inclusion/Exclusion criteria apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 90 years old?
  • Has a doctor told you that you have Alzheimer's disease?
  • Do you have agitation caused by Alzheimer's disease, such as being restless or aggressive?
  • Have you taken part in an earlier study of the same medicine (KarXT or ML-007C-MA) and finished it?
  • Do you have a caregiver or trial partner who sees you regularly and can help with the study?

Where in South Korea

Also in 25 other countries, 231 sites

  • Deagu, Taegu-KwangyǒkshiHospital not named in the registryContact: Site 2400Not yet recruiting
  • IncheonHospital not named in the registryContact: Site 2409Not yet recruiting
  • Inha University HospitalIncheon, South KoreaContact: Seong Hye Choi, Site 2401Taking people
  • SeoulHospital not named in the registryContact: Site 2402Not yet recruiting
  • SeoulHospital not named in the registryContact: Site 2405Not yet recruiting
  • Gangnam Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Hanna Cho, Site 2408Taking people
  • Konkuk University Medical CenterSeoul, South KoreaContact: Seol-Heui Han, Site 2403Taking people
  • Seoul National University HospitalSeoul, South KoreaContact: Manho Kim, Site 2407Taking people
  • The Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaContact: Hyun-Kook Lim, Site 2404Taking people
  • Seoul, Seoul-teukbyeolsi [Seoul]Hospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

The group in the trial

  • KarXT+KarX-ECTreatment being tested

    Treatment: KarXT and KarX-EC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
Plain-language title
Long-term study of KarXT and KarX-EC for agitation in Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06937229, who can take part
Record updated
12 November 2026